Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) have earned an average rating of “Moderate Buy” from the five analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $20.00.

A number of brokerages have recently weighed in on NBTX. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. TD Cowen began coverage on Nanobiotix in a research report on Friday, February 6th. They issued a “buy” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Finally, Guggenheim upped their price target on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th.

Nanobiotix Stock Up 17.5%

Shares of NASDAQ:NBTX opened at $35.93 on Thursday. Nanobiotix has a fifty-two week low of $2.95 and a fifty-two week high of $37.11. The firm has a 50-day simple moving average of $23.47 and a 200 day simple moving average of $19.92.

Institutional Investors Weigh In On Nanobiotix

A number of hedge funds have recently made changes to their positions in NBTX. Millennium Management LLC bought a new position in Nanobiotix in the 4th quarter worth approximately $390,000. Marshall Wace LLP acquired a new position in shares of Nanobiotix during the fourth quarter valued at $220,000. Optiver Holding B.V. acquired a new position in shares of Nanobiotix during the third quarter valued at $101,000. Finally, Royal Bank of Canada raised its stake in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.